Intra-Cellular Therapies, Inc. (ITCI)
USD 131.87
(0.0%)
USD 131.87
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 464.37 Million USD | 85.51% |
| 2022 | 249.13 Million USD | 204.91% |
| 2021 | 81.7 Million USD | 262.65% |
| 2020 | 22.53 Million USD | 37071.49% |
| 2019 | 60.61 Thousand USD | 0.0% |
| 2018 | - USD | -100.0% |
| 2017 | 245.83 Thousand USD | -25.66% |
| 2016 | 330.7 Thousand USD | 261.96% |
| 2015 | 91.36 Thousand USD | -84.17% |
| 2014 | 577.3 Thousand USD | -78.91% |
| 2013 | 2.73 Million USD | -12.22% |
| 2012 | 3.11 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 144.86 Million USD | 10.16% |
| 2024 Q3 | 175.15 Million USD | 8.53% |
| 2024 Q2 | 161.38 Million USD | 11.41% |
| 2023 Q4 | 131.5 Million USD | 4.53% |
| 2023 FY | 462.17 Million USD | 85.51% |
| 2023 Q1 | 94.73 Million USD | 8.35% |
| 2023 Q2 | 110.12 Million USD | 16.25% |
| 2023 Q3 | 125.81 Million USD | 14.24% |
| 2022 FY | 249.13 Million USD | 204.91% |
| 2022 Q4 | 87.43 Million USD | 21.65% |
| 2022 Q3 | 71.87 Million USD | 30.5% |
| 2022 Q2 | 55.07 Million USD | 58.46% |
| 2022 Q1 | 34.75 Million USD | 36.21% |
| 2021 Q4 | 25.51 Million USD | 18.1% |
| 2021 Q3 | 21.6 Million USD | 13.68% |
| 2021 FY | 81.7 Million USD | 262.65% |
| 2021 Q1 | 15.57 Million USD | 25.6% |
| 2021 Q2 | 19 Million USD | 22.0% |
| 2020 Q1 | 882.51 Thousand USD | 1355.98% |
| 2020 FY | 22.53 Million USD | 37071.49% |
| 2020 Q2 | 1.87 Million USD | 112.56% |
| 2020 Q3 | 7.36 Million USD | 292.81% |
| 2020 Q4 | 12.4 Million USD | 68.33% |
| 2019 Q1 | - USD | 0.0% |
| 2019 Q4 | 60.61 Thousand USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 FY | 60.61 Thousand USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 FY | - USD | -100.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | -100.0% |
| 2017 Q3 | 30.75 Thousand USD | -73.2% |
| 2017 Q2 | 114.74 Thousand USD | 20.42% |
| 2017 Q1 | 95.28 Thousand USD | -2.66% |
| 2017 FY | 245.83 Thousand USD | -25.66% |
| 2017 Q4 | 5055.00 USD | -83.56% |
| 2016 Q4 | 97.89 Thousand USD | 2144.27% |
| 2016 Q3 | 4362.00 USD | -98.09% |
| 2016 FY | 330.7 Thousand USD | 261.96% |
| 2016 Q1 | - USD | -100.0% |
| 2016 Q2 | 228.44 Thousand USD | 0.0% |
| 2015 Q2 | 57.39 Thousand USD | 1631.22% |
| 2015 FY | 91.36 Thousand USD | -84.17% |
| 2015 Q4 | 30.65 Thousand USD | 0.0% |
| 2015 Q3 | - USD | -100.0% |
| 2015 Q1 | 3315.00 USD | -94.97% |
| 2014 Q4 | 65.86 Thousand USD | -47.06% |
| 2014 Q2 | 219.23 Thousand USD | 30.66% |
| 2014 Q3 | 124.41 Thousand USD | -43.25% |
| 2014 FY | 577.3 Thousand USD | -78.91% |
| 2014 Q1 | 167.78 Thousand USD | -79.72% |
| 2013 Q2 | 643.26 Thousand USD | 7.52% |
| 2013 Q3 | 667.95 Thousand USD | 3.84% |
| 2013 Q1 | 598.25 Thousand USD | -10.57% |
| 2013 FY | 2.73 Million USD | -12.22% |
| 2013 Q4 | 827.53 Thousand USD | 23.89% |
| 2012 Q4 | 668.93 Thousand USD | 0.0% |
| 2012 FY | 3.11 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| PainReform Ltd. | - USD | -Infinity% |
| Alvotech | 91.43 Million USD | -407.875% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 18.067% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 4.611% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | -818.036% |
| Journey Medical Corporation | 79.18 Million USD | -486.466% |
| Dynavax Technologies Corporation | 232.28 Million USD | -99.915% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -299.17% |
| Bright Green Corporation | 401.49 Thousand USD | -115561.372% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 31.202% |
| Embecta Corp. | 1.12 Billion USD | 58.568% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -1827.423% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -1827.423% |
| SCYNEXIS, Inc. | 140.14 Million USD | -231.359% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -7875.594% |
| Silver Spike Investment Corp. | 11.72 Million USD | -3861.48% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -23979.374% |
| Alpha Teknova, Inc. | 36.68 Million USD | -1165.865% |
| Safety Shot Inc | 202.67 Thousand USD | -229026.166% |
| Procaps Group, S.A. | 409.92 Million USD | -13.283% |
| Cosmos Health Inc. | 53.37 Million USD | -769.984% |
| Theratechnologies Inc. | 81.76 Million USD | -467.939% |
| Harrow Health, Inc. | 130.19 Million USD | -256.678% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -3546.408% |
| Biofrontera Inc. | 34.07 Million USD | -1262.948% |
| DURECT Corporation | 8.54 Million USD | -5332.499% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 23.563% |
| Cronos Group Inc. | 88.84 Million USD | -422.698% |
| OptiNose, Inc. | 70.98 Million USD | -554.162% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | -4.887% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -7029.705% |
| Organogenesis Holdings Inc. | 433.14 Million USD | -7.21% |
| Guardion Health Sciences, Inc. | 12.24 Million USD | -3691.224% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -1074.06% |
| Radius Health, Inc. | 2.88 Billion USD | 83.888% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -1337.289% |
| ProPhase Labs, Inc. | 44.38 Million USD | -946.255% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 54.37% |
| Procaps Group S.A. | 409.92 Million USD | -13.283% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -35565.899% |
| Viatris Inc. | 15.42 Billion USD | 96.99% |
| Rockwell Medical, Inc. | 83.61 Million USD | -455.387% |
| Aytu BioPharma, Inc. | 81 Million USD | -473.282% |
| SIGA Technologies, Inc. | 139.91 Million USD | -231.889% |
| Tilray Brands, Inc. | 788.94 Million USD | 41.14% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | -262.051% |
| Shineco, Inc. | 9.8 Million USD | -4637.572% |
| PetIQ, Inc. | 1.1 Billion USD | 57.86% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 12 Thousand USD | -3869650.0% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 75.392% |
| Alimera Sciences, Inc. | 80.75 Million USD | -475.043% |
| Assertio Holdings, Inc. | 152.06 Million USD | -205.368% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Clever Leaves Holdings Inc. | 17.41 Million USD | -2566.188% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -43040.825% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -1560.659% |
| Hempacco Co., Inc. | 4.04 Million USD | -11378.291% |
| Talphera, Inc. | 651 Thousand USD | -71231.797% |
| Alvotech | 91.43 Million USD | -407.875% |
| Eagle Pharmaceuticals, Inc. | 316.61 Million USD | -46.669% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 64.181% |
| Currenc Group, Inc. | 53.25 Million USD | -771.969% |
| Kamada Ltd. | 144.75 Million USD | -220.789% |
| Indivior PLC | 1.09 Billion USD | 57.514% |
| Evoke Pharma, Inc. | 5.18 Million USD | -8863.582% |
| Flora Growth Corp. | 76.07 Million USD | -510.443% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -43040.825% |
| Evolus, Inc. | 202.08 Million USD | -129.789% |
| HUTCHMED (China) Limited | 837.99 Million USD | 44.586% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 27.937% |
| Akanda Corp. | 2.16 Million USD | -21398.094% |